Ruling is a significant setback for the often religious backed anti-abortion movement

Supreme Court rejects challenge to abortion pill mifepristone, allowing drug to stay on the market.


The Supreme Court on Thursday rejected a lawsuit challenging the Food and Drug Administration’s approach to regulating the abortion pill mifepristone with a ruling that will continue to allow the pills to be mailed to patients without an in-person doctor’s visit.

The ruling is a significant setback for the anti-abortion movement in what was the first major Supreme Court case on reproductive rights since the court’s conservative majority overturned Roe v. Wade in 2022.

See full article here.